A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
In this study, the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended
phase II dose (RP2D), the preliminary efficacy, pharmacokinetic characteristics, and
immunogenicity of BL-B01D1 will be investigated in patients with unresectable locally
advanced or metastatic breast cancer and other solid tumors.